Document is current
Any future updates will be listed below
-
Authors
Armstrong, April W. https://orcid.org/0000-0003-0064-8707
Mburu, Sicily https://orcid.org/0000-0003-1296-4520
Gondo, George C. https://orcid.org/0000-0002-6468-0397
Kornyeyeva, Elena
Frade, Susan
Ogdie, Alexis https://orcid.org/0000-0002-4639-0775
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
- License Information
-
More Information
Article History
Accepted: 12 May 2025
First Online: 29 August 2025
Declarations
:
: The study, medical writing support, and open access fee for this manuscript were funded by Novartis AG.
: A.W.A. has served as a research investigator, scientific advisor, and/or speaker at AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, LEO Pharma, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer. S.M. receives no individual compensation and is employed by IFPA. In the past 12 months, IFPA has accepted grants and funding from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Leo Pharma, Eli Lilly, Novartis, Pfizer, and UCB. G.C.G. is an employee of The National Psoriasis Foundation. E.K. was a full-time employee of Novartis Pharma AG, Basel, Switzerland. S.F. is a full-time employee of Novartis Pharma AG, Basel, Switzerland. A.O. serves as a consultant of AbbVie, Amgen, BMS, Celgene, CorEvitas, Eli Lilly, GSK, Gilead, Janssen, Merck, Novartis, Pfizer, Spyre Therapeutics, Takeda, Treg Therapeutics, and UCB Pharma and has received grants and/or research support from AbbVie, Amgen, BMS, Janssen, Novartis, Pfizer, UCB, Forward/National Databank for Rheumatic Diseases, NIH/NIAMS, PPACMAN, Rheumatology Research Foundation, and The National Psoriasis Foundation.
: Results analyzed during this study are included in this published article and its supplementary information files; additional data may be available upon request from Novartis on a case-by-case basis.
: An institutional review board (Pearl IRB) considered this study to be exempt from ethics approval according to FDA 21 CFR 56.104 and 45CFR46.104(b)(2):(2).
: Informed digital consent was obtained from patients before study participation. The procedure for obtaining electronic informed consent was outlined in the Psoriasis and Beyond study protocol, which was reviewed and approved according to local laws and regulations.
: Not applicable.
: Not applicable.
: A.W.A., A.O., S.F., and S.M.: study conception and design, data interpretation, and writing/revision of the manuscript. E.K. and G.C.G.: data interpretation and writing/revision of the manuscript. All authors reviewed and approved the final version of the manuscript for submission.
